What happened in optometry this week: December 9 - December 13
Catch up on what happened in optometry during the week of December 9-December 13.
Catch up with what Optometry Times shared this week:
Galimedix Therapeutics initiates Phase 1 trial of oral GAL-101
By David Hutton, Managing Editor, Ophthalmology Times
Galimedix Therapeutics Inc. announced the initiation of dosing in its phase 1 clinical trial evaluating oral GAL-101, an amyloid beta (Aβ) aggregation modulator. This trial is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of the orally administered therapy.
What will myopia control look like in 2034?
By Hattie Hayes and Carly Lam, PhD, MSc
In the world of pediatric ophthalmology and optometry, myopia control is the center of many conversations. For practitioners who want to stymie the disease’s progression, and parents who want to help their children take control of their eye health, one particular technology is growing increasingly in demand. Carly Lam, PhD, MSc, the immediate past president of the Asia Pacific Council of Optometry, is also a crucial figure in the development of defocus incorporated multiple segments (DIMS) lenses. Her research led to the development of DIMS spectacle lenses and their soft-contact counterpart. Now a growing body of research supports Lam’s view that DIMS spectacle lenses could relieve some of the worldwide problems presented by childhood and adult myopia.
Tenpoint Therapeutics and Visus Therapeutics merge
By Emily Kaiser Maharjan, Assistant Managing Editor
Tenpoint Therapeutics Ltd. and Visus Therapeutics Inc. have completed their merger, consolidating their respective ophthalmic therapeutic assets. The new entity aims to address ocular conditions related to aging, with a focus on presbyopia, cataracts, and geographic atrophy.
A central component of the merged portfolio is BRIMOCHOL PF, a once-daily, presbyopia-correcting eye drop. The product combines carbachol, a miotic agent, with brimonidine, an alpha2-agonist.1
Results released in 4-year myopia control study of Diffusion Optics Technology in children
By Lynda Charters
The results of a recent study showed that Diffusion Optics Technology (DOT) 0.2 spectacle lenses (SightGlass Vision) are safe and effective for reducing myopia progression in young children. The lenses showed an additional benefit in the 4th year of wear. The study results supported the hypothesis that a mild reduction in retinal contrast can slow myopia progression in young children,1 according to senior author James S. Wolffsohn, MB, PhD, who is professor of optometry, College of Health and Life Sciences, Aston University, Birmingham, UK.
The whys and wherefores of Demodex blepharitis
By Lynda Charters
Participants at a recent Optometry Times Case-Based Roundtable® discussion emphasized the importance of diagnosing and treating Demodex blepharitis as a key component of a comprehensive evaluation of patients with dry eye disease.
Christopher E. Starr, MD, FACS, shared the highlights from the discussion. Starr is an associate professor of ophthalmology, director of laser vision correction and refractive surgery service, and director of ophthalmic education at Weill Cornell Medicine, New York Presbyterian Hospital in New York.
